PP
ALDR

PDT Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

PDT Partners’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-124,177
Closed -$1.96M – 567
2018
Q2 		$1.96M Buy
124,177
+1,277
+1% +$19.4K 0.07% 260
2018
Q1 		$1.56M Sell
122,900
-230,200
-65% -$3.33M 0.05% 314
2017
Q4 		$4.04M Sell
353,100
-87,388
-20% -$975K 0.12% 215
2017
Q3 		$5.4M Buy
+440,488
New +$4.59M 0.18% 173
2016
Q1 		– Sell
-45,355
Closed -$1.5M – 616
2015
Q4 		$1.5M Buy
45,355
+7,355
+19% +$249K 0.21% 174
2015
Q3 		$1.25M Sell
38,000
-15,358
-29% -$653K 0.03% 645
2015
Q2 		$2.83M Buy
53,358
+11,958
+29% +$435K 0.07% 318
2015
Q1 		$1.2M Buy
41,400
+29,198
+239% +$801K 0.03% 714
2014
Q4 		$355K Sell
12,202
-712
-6% -$12.8K 0.03% 501
2014
Q3 		$164K Buy
+12,914
New +$195K ﹤0.01% 1209

Other funds holding ALDR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PDT Partners's ALDR Position: Q3 2018 in Review

PDT Partners sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 124,177 shares — an estimated $1.96M sold.

PDT Partners first reported a position in ALDR in Q3 2014 and held it in 10 quarters. The position peaked at $5.4M in Q3 2017. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

  • PDT Partners reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • PDT Partners sold 124,177 Alder Biopharmaceuticals shares in Q3 2018, an estimated $1.96M.
  • PDT Partners first reported a position in Alder Biopharmaceuticals in Q3 2014 and held it in 10 quarters.
  • PDT Partners's Alder Biopharmaceuticals position peaked at $5.4M in Q3 2017.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on PDT Partners's 13F filing for Q3 2018, filed 14 Nov 2018.